INS and myotonic dystrophy type 1: The role of insulin signaling in DM1 is further supported by clinical trials using metformin, which has shown promising effects on exercise capacity and mobility in DM1 patients (Bassez et al., 2018) and is established as an effective treatment for hyperglycemia in DM1 (Kouki et al., 2005).